<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003387" GROUP_ID="DEPRESSN" ID="873500102009062738" MERGED_FROM="" MODIFIED="2008-11-06 02:51:12 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;/p&gt;&lt;p&gt;Old title: - TSC OK - REVIEWER OK - FOR SUBMISSION - Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder&lt;/p&gt;" NOTES_MODIFIED="2008-11-06 01:48:09 +0000" NOTES_MODIFIED_BY="Rachel Churchill" REVIEW_NO="044" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2008-11-06 02:51:12 +0100" MODIFIED_BY="Rachel Churchill">
<TITLE>Transcranial magnetic stimulation for the treatment of obsessive-compulsive disorder</TITLE>
<CONTACT MODIFIED="2008-11-06 02:51:12 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="14989" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>José Luis</FIRST_NAME><LAST_NAME>Rodriguez-Martin</LAST_NAME><POSITION>Head of Department</POSITION><EMAIL_1>jlrmartin@jccm.es</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Research</DEPARTMENT><ORGANISATION>Foundation for Health Research in Castilla-La Mancha (FISCAM)</ORGANISATION><ADDRESS_1>C/ Berna, Nº2, Local 0-2</ADDRESS_1><CITY>Toledo</CITY><REGION>45003</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34-925-28-11-44</PHONE_1><FAX_1>+34-925-28-11-49</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-06 02:51:12 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="14989" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>José Luis</FIRST_NAME><LAST_NAME>Rodriguez-Martin</LAST_NAME><POSITION>Head of Department</POSITION><EMAIL_1>jlrmartin@jccm.es</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Research</DEPARTMENT><ORGANISATION>Foundation for Health Research in Castilla-La Mancha (FISCAM)</ORGANISATION><ADDRESS_1>C/ Berna, Nº2, Local 0-2</ADDRESS_1><CITY>Toledo</CITY><REGION>45003</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34-925-28-11-44</PHONE_1><FAX_1>+34-925-28-11-49</FAX_1></ADDRESS></PERSON><PERSON ID="13102" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>José Manuel</FIRST_NAME><LAST_NAME>Barbanoj</LAST_NAME><POSITION>Researcher</POSITION><ADDRESS><DEPARTMENT>Department of Farmacology</DEPARTMENT><ORGANISATION>Hospital de la Santa Creu i Sant Pau</ORGANISATION><CITY>Barcelona</CITY><REGION>Catalonia</REGION><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON><PERSON ID="13201" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>V</FIRST_NAME><LAST_NAME>Pérez </LAST_NAME><POSITION>Psychiatrist</POSITION><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>Hospital de la Santa Creu i Sant Pau</ORGANISATION><CITY>Barcelona</CITY><REGION>Catalonia</REGION><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON><PERSON ID="13216" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>M</FIRST_NAME><LAST_NAME>Sacristan</LAST_NAME><POSITION>Researcher</POSITION><ADDRESS><DEPARTMENT>Department of Epidemiology</DEPARTMENT><ORGANISATION>Hospital de la Santa Creu i Sant Pau</ORGANISATION><CITY>Barcelona</CITY><REGION>Catalonia</REGION><COUNTRY CODE="ES">Spain</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-06 01:33:02 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 15/04/03&lt;/p&gt;" NOTES_MODIFIED="2008-11-06 01:33:02 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="5" MONTH="12" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="12" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="2" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2003"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="6" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="5" MONTH="12" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Institut de Recerca del Hospital de la Santa Creu i Sant Pau (Barcelona)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Centro Cochrane Iberoamericano (Barcelona)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Hospital de la Santa Creu i Sant Pau (Barcelona)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Fundación para la Investigación Sanitaria en Castilla-La Mancha FISCAM (Toledo)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Instituto de Salud Carlos III (Madrid)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-06 01:39:07 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-06 01:38:13 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-06 01:38:13 +0000" MODIFIED_BY="[Empty name]">Transcranial magnetic stimulation (TMS) for the treatment of obsessive compulsive disorder (OCD)</TITLE>
<SUMMARY_BODY>
<P>Transcranial magnetic stimulation was introduced as neurophysiological technique in 1985 when Anthony Barker and his team developed a compact machine that permitted a non-invasive stimulation of the cerebral cortex. In addition it has been suggested that TMS could have therapeutic potential. Its' capability for excitation or inhibition of cortical areas in a non-invasive way represents a remarkable advance in neuroscience researches. Some studies have evaluated the therapeutic effects of repetitive TMS in controlled studies on patients with obsessive-compulsive disorder observing some changes in their behaviour in terms of compulsive urges or improvements in mood. This review has evaluated the current evidence for TMS as a therapeutic treatment for obsessive-compulsive disorder (OCD). There is a lack of evidence for the effect of TMS in the treatment of OCD. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Transcranial magnetic stimulation (TMS) was introduced as a neurophysiological technique in 1985 when Anthony Barker and his team developed a compact machine that permitted non-invasive stimulation of the cerebral cortex (Barker 1985). Since its introduction, TMS has been used to evaluate the motor system, to study the function of several cerebral regions, and for the pathophysiology of several neuropsychiatric illnesses. In addition, it has been suggested that TMS might have therapeutic potential. </P>
<P>Some controlled studies have evaluated the effects of repetitive TMS (rTMS) in patients with obsessive-compulsive disorder (OCD). Greenberg (Greenberg 1997) observed that a single session of right prefrontal cortex stimulation produced a significant decrease in compulsive urges in OCD patients lasting over eight hours. Other studies have reported transitory improvements in mood but there are no observations for changes in anxiety or obsessions.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To develop a systematic review on the clinical efficacy and safety of transcranial magnetic stimulation from randomised controlled trials in the treatment of obsessive-compulsive disorder.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>An electronic search was performed including the Cochrane Collaboration Depression, Anxiety and Neurosis Review Group trials register (last searched June, 2002), the Cochrane Controlled Trials Register (Issue 2, 2002), MEDLINE (1966-2002), EMBASE (1974-2002), PsycLIT (1980-2002), and bibliographies from reviewed articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials assessing the therapeutic efficacy and safety of transcranial magnetic stimulation for obsessive-compulsive disorder. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>All reviewers independently extracted the information and verified it by cross-checking. Disagreements were resolved through discussion. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Three trials were included in the review and only two contained data in a suitable form for quantitative analysis. It was not possible to pool any results for a meta-analysis. No difference was seen between rTMS and sham TMS using the Yale-Brown Obsessive-Compulsive Scale or the Hamilton Depression Rating Scale for all time periods analysed.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There are currently insufficient data from randomised controlled trials to draw any conclusions about the efficacy of transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-06 01:39:07 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-06 01:39:07 +0000" MODIFIED_BY="[Empty name]">
<P>Transcranial magnetic stimulation (TMS) was introduced as a neurophysiological technique in 1985 when Anthony Barker and his team developed a compact machine that permitted non-invasive stimulation of the cerebral cortex (<LINK REF="REF-Barker-1985" TYPE="REFERENCE">Barker 1985</LINK>). Since its introduction, TMS has been used to evaluate the motor system, to study the function of several regions of the brain, and to study the pathophysiology study of several neuropsychiatric illnesses. However, it has also been suggested TMS could be used as a treatment.</P>
<P>Repetitive transcranial magnetic stimulation (rTMS) is a term used to describe the rhythmic and repetitive application of TMS. Stimulation faster than once per a second (&gt;1Hz) is called high frequency rTMS, slower stimulation (&lt;=1Hz) is called low frequency rTMS. Low frequency rTMS is thought to inhibit cortical stimulation in certain regions, while high frequency rTMS activates stimulated areas.</P>
<P>Some controlled studies have evaluated the therapeutic effects of rTMS in patients with obsessive-compulsive disorder (OCD). Greenberg (<LINK REF="STD-Greenberg-1997" TYPE="STUDY">Greenberg 1997</LINK>) observed that a single session of right prefrontal cortex stimulation produced a significant decrease in compulsive urges lasting over eight hours in OCD patients. Other studies have reported transitory improvements in mood but there are no observations for changes in anxiety or obsessive symptoms.</P>
<P>OCD is a chronic anxiety disorder (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>). Typical symptoms include persistent and recurrent thoughts or mental images (that the sufferer realises are inappropriate), and compulsions taking the form of repetitive behaviours or mental acts in response to obsessions. Obsessions are often related to thoughts about contamination (from contact with other people or materials), and typical compulsions are cleaning, washing (e.g. hands), praying, counting, or checking the same things hundred of times in a pathological way.</P>
<P>OCD can seriously disrupt normal daily routine, leading to low quality of life, social impairment, and continuous mental distress (since sufferers know that their thoughts and behaviours are irrational). OCD has a prevalence of about two per cent. It has a chronic course, and often does not respond to conventional pharmacotherapy.</P>
<P>This systematic review aims to evaluate current evidence concerning transcranial magnetic stimulation technique as a therapeutic treatment for OCD.<BR/>
</P>
</BACKGROUND>
<OBJECTIVES>
<P>To develop a systematic review on the clinical efficacy and safety of the transcranial magnetic stimulation from randomised controlled trials in the treatment of obsessive-compulsive disorder.<BR/> </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All identified, relevant randomised controlled trials assessing the therapeutic efficacy and safety of transcranial magnetic stimulation for obsessive-compulsive disorder were included. Quasi-randomised study designs were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All persons with obsessive-compulsive disorder diagnosed by any recognised criteria, irrespective of gender, age or nationality. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>A) The application of transcranial magnetic stimulation (TMS) versus: </P>
<P>1. No intervention.<BR/>2. Sham TMS.<BR/>3. Psychotherapy (sub-group analysis by different types of therapy).<BR/>4. Psychotropic drugs (sub-group analysis by different types of drugs). <BR/>5. Any other therapy (without drugs or psychotherapy).<BR/>6. (r)TMS + other therapies or drugs vs sham (r)TMS + the same therapies or drugs.</P>
<P>B) One technique of TMS versus another: </P>
<P>1. High frequency vs low frequency.<BR/>2. Right prefrontal cortex vs left prefrontal cortex.<BR/>3. Single pulse vs repetitive pulse.<BR/>4. Length of treatment (sub-group analysis by number of weeks).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>In this review the primary outcome was remission of symptoms, determined by any of the following measures: time to adjunctive treatment, readmission to hospital or hospital discharge, time off work or by appropriate psychometric scales.</P>
<P>Other outcomes with a clinical interest are: </P>
<P>a) Functioning to short, medium and long term <BR/>b) Individual / social behaviour <BR/>c) Quality of life<BR/>d) Global impression<BR/>e) Acceptability of treatment (as measured by withdrawal from trial)<BR/>f) Safety as measured by the incidence of adverse effects ( including side-effects ) <BR/>g) Mortality.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: Collaborative Review Group search strategy. <BR/>The Cochrane Collaboration Depression, Anxiety and Neurosis Review Group's search strategy and the Iberoamerican Cochrane Centre search strategy were used to search MEDLINE (1966-2002), EMBASE (1974-2002), PsycLIT (1980-2002), the Cochrane Collaboration Depression, Anxiety and Neurosis Review Group trials register (last searched June, 2001), the Cochrane Controlled Trials Register (Issue 2, 2002). Date of last search in MEDLINE: 18 June 2002. </P>
<P>Electronic Searches<BR/>The following databases were searched using "Magnetic Stimulation" or rTMS or TMS</P>
<P>MEDLINE (1966-2002), <BR/>EMBASE (1974-2002), <BR/>PsycLIT (1980-2002), <BR/>the Cochrane Collaboration Depression, Neurosis and Anxiety Review Group trials register, <BR/>the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 22, 2002). </P>
<P>Personal Communication;<BR/>Unpublished data and grey literature were searched through personal communications with researchers and others with an interest in the field. <BR/>When possible, the corresponding authors of identified RCTs were contacted for additional information about other relevant studies. </P>
<P>Handsearches;<BR/>Bibliographies of included studies were checked.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Study selection <BR/>The reviewers independently evaluated all the identified articles without taking the results into consideration. Potentially relevant studies were identified from the references retrieved from the search. If the summary appeared relevant the complete text was obtained for an evaluation of its methodological quality. </P>
<P>Quality assessment <BR/>The quality of randomisation and allocation concealment for each trial was assessed using the methods described in the Cochrane Collaboration Handbook (<LINK REF="REF-Clarke-2001" TYPE="REFERENCE">Clarke 2001</LINK>). </P>
<P>Data collection<BR/>All reviewers independently extracted the information and verified it with cross-checking. Disagreements were resolved through discussion.</P>
<P>Data synthesis<BR/>For cross-over studies we tried to exclude a possible carry-over effect between different phases by using only information from the first phase of such studies. </P>
<P>Incomplete data: it was agreed not to include studies with more than 40% withdrawals in the final quantitative analysis, as this level of withdrawal could threaten the validity of the results. </P>
<P>Continuous data: for continuous variables (psychometric test scores) the results of the individual studies were calculated as mean difference. For a pooled analysis, in the case of data becoming available in the future, the results will be calculated as weighted (or standardised) mean differences under a fixed effect model, weighted by the inverse variance method and with 95% confidence intervals (CIs). In the case of available binary data we will use the relative risk using a fixed effect model and the Mantel-Haenszel method with 95% CIs. If statistical heterogeneity is suspected, a random effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) will be used. Statistical heterogeneity will be evaluated by an inspection of the graphs and chi-squared tests.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Only three trials that met our inclusion criteria were identified. One of the trials (<LINK REF="STD-Alonso-2001" TYPE="STUDY">Alonso 2001</LINK>) used a double-blind, randomised, placebo-controlled parallel groups design of six weeks' treatment plus four weeks follow-up. This trial included 18 outpatients who met DSM-IV criteria for OCD. Five of these patients were not taking any other medications and the rest had been taking a stable dose of medication for at least 12 weeks. The second trial (<LINK REF="STD-Sachdev-2001" TYPE="STUDY">Sachdev 2001</LINK>) compared right vs left prefrontal rTMS without a placebo arm in 12 OCD subjects. Patients received treatment for two weeks' treatment with an evaluation at one and two weeks and one month later. The third study (<LINK REF="STD-Greenberg-1997" TYPE="STUDY">Greenberg 1997</LINK>) used a randomised, double-blind, crossover design. It studied 12 OCD patients with an evaluation 12 hours after stimulation. This study has been excluded from the quantitative analysis of this review because data from the first phase of the trial were not available. </P>
<P>See: characteristics of included studies table. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Randomisation and allocation concealment<BR/>The studies included in the statistical analysis of this review (<LINK REF="STD-Alonso-2001" TYPE="STUDY">Alonso 2001</LINK>) (<LINK REF="STD-Sachdev-2001" TYPE="STUDY">Sachdev 2001</LINK>) have been included in category B, as they do not describe the method of concealment allocation used and only give a general description of randomisation. </P>
<P>Blinding of intervention<BR/>When administering TMS it is impossible to blind the person who administers the technique (i.e. the physician who applies the treatment or control) and double-blind therefore refers to the patient and outcome assessor.</P>
<P>Follow-up<BR/>In these two studies all subjects completed the protocol.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Low frequency rTMS over the right dorsolateral prefrontal cortex versus sham TMS. </P>
<P>Outcome: Remission of obsessions and/or compulsions. </P>
<P>1. Yale-Brown Obsessive Compulsive Scale (6 weeks). Only one study contributed to this analysis with data from 18 patients (10 in the treatment group and 8 in the placebo group). Sub-category analysis was carried out by obsessions, compulsions and total score. For obsessions, the mean difference (MD) for the rTMS versus sham TMS, was -2.10 (95% CI -5.82 to 1.62 p = 0.3). For compulsions the MD between rTMS and placebo was -0.90 (95% CI -6.27 to 4.47 p= 0.7). For total score, the MD for the rTMS versus sham TMS was -3.10 (95% CI -10.75 to 4.55; p = 0.4).</P>
<P>Yale-Brown Obsessive Compulsive Scale (10 weeks). The same study contributed to this analysis with data from 18 patients (10 in the treatment group and 8 in the placebo group). Sub-category analysis was carried out by obsessions, compulsions and total score. For obsessions, the mean difference (MD) for the rTMS versus sham TMS, was -3.00 (95% CI -7.01to 1.01 p = 0.14). For compulsions the MD between rTMS and placebo was -1.30 (95% CI -6.51to 3.91 p= 0.6). For total score, the MD for the rTMS versus sham TMS was -4.70 (95% CI -12.76 to 3.36 p = 0.3).</P>
<P>Outcome: Remission of depression.</P>
<P>1. Hamilton depression Rating Scale (6 weeks). Only one study contributed to this analysis with data from 18 patients (10 in the treatment group and 8 in the placebo group). For depression, the mean difference (MD) for the rTMS versus sham TMS was -1.10 (95% CI -5.03 to 2.83 p= 0.6).</P>
<P>Hamilton Depression Rating Scale (10 weeks). The same study contributed to this analysis with data from 18 patients (10 in the treatment group and 8 in the placebo group). The mean difference (MD) for the rTMS versus sham TMS was -1.20 (95% CI -4.83 to 2.43 p= 0.5). </P>
<P>High frequency rTMS over the right dorsolateral prefrontal cortex versus left dorsolateral prefrontal cortex </P>
<P>Outcome: Remission of obsessions and/or compulsions. </P>
<P>1. Yale-Brown Obsessive Compulsive Scale (2 weeks treatment and 1 month follow-up). Only one study contributed to this analysis with data from 12 patients (6 in the treatment group and 6 in the placebo group). Sub-category analysis was carried out by obsessions, compulsions and total score. After two weeks, the mean difference (MD) for obsessions for right-rTMS versus left-rTMS, was 2.33 (95% CI -3.82 to 18.48 p = 0.5). For compulsions the MD between right-rTMS versus left-rTMS was -2.00 (95% CI -8.45 to 4.45 p= 0.5). For total score, the MD for right-rTMS versus left-rTMS was 0.33 (95% CI -10.26 to 10.92; p = 1). At one month follow-up the MD for obsessions for right-rTMS versus left-rTMS, was -2.10 (95% CI -5.95 to 1.75 p = 0.3). For compulsions the MD between right-rTMS versus left-rTMS was -2.40 (95% CI -6.87 to 2.07 p= 0.3). For total score, the MD for right-rTMS versus left-rTMS was -4.50 (95% CI -11.86 to 2.86; p = 0.2).</P>
<P>Outcome: Remission of depression.</P>
<P>1. Beck Depression Inventory (2 weeks treatment and 1 month follow-up). Only one study contributed to this analysis with data from 12 patients (6 in the treatment group and 6 in the placebo group). At two weeks the mean difference (MD) in depression for right-rTMS versus left-rTMS was 4.50 (95% CI -5.22 to 14.22 p = 0.4). At one month follow-up the MD for depression for right-rTMS versus left-rTMS was 0.77(95% CI -12.50 to 14.04 p = 0.9).</P>
<P>2. Montgomery-Asberg Depression Rating Scale (2 weeks treatment and 1 month follow-up). Only one study contributed to this analysis with data from 12 patients (6 in the treatment group and 6 in the placebo group). At two weeks, the mean difference (MD) for depression for right-rTMS versus left-rTMS was 9.33 (95% CI -0.90 to 19.56 p = 0.07). At one month follow-up the MD for right-rTMS versus left-rTMS, was 5.37(95% CI -3.03 to 13.77 p = 0.2). </P>
<P>Outcome: Remission of anxiety.<BR/> <BR/>1. Spielberger State-Trait Anxiety Inventory-State (2 weeks treatment and 1 month follow-up). Only one study contributed to this analysis with data from 12 patients (6 in the treatment group and 6 in the placebo group). At two weeks the mean difference (MD) in anxiety for right-rTMS versus left-rTMS was 0.50 (95% CI -13.79 to 14.79 p = 0.9). At one month follow-up the MD for anxiety for right-rTMS versus left-rTMS, was -0.83 (95% CI -19.10 to 17.44 p = 0.9).</P>
<P>There were no statistically significant findings. </P>
<P>The evaluation of safety and adverse effects will be done in an update of this review as currently there are insufficient data available. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>It is not possible to draw any conclusions from this review. Before the use of transcranial magnetic stimulation can be recommended for patients with obsessive compulsive disorder further large, randomised placebo-controlled trials are needed for its evaluation. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is no reliable evidence on which to base a decision to use transcranial magnetic stimulation to treat patients with obsessive-compulsive disorder. It is not yet possible to recommend routine use of TMS for treating OCD. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There are currently insufficient data from randomised controlled trials to draw any conclusions about the efficacy of transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder. Further large randomised-controlled trials are required to evaluate its' efficacy</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The reviewers are grateful for the advice and support of the Cochrane Collaboration Depression Anxiety and Neurosis Review Group, Miren Fernández from Iberoamerican Cochrane Centre and Julio Vallejo from Bellvitge University Hospital. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P> None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>JL - drafts of the review, methodological aspects and statistical aspects, correspondence <BR/>MBR - methodological aspects of review<BR/>VP and MS - clinical aspects of the review </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>This review is in the process of being updated.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Alonso-2001" NAME="Alonso 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alonso P, Pujol J, Cardoner N, Benlloch L, Deus J, Menchon JM et al</AU>
<TI>Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>158</VL>
<NO>7</NO>
<PG>1143-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-1997" NAME="Greenberg 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg BD, George MS, Martin JD, Benjamin J, Schlaepfer TE, Altemus M et al</AU>
<TI>Effect of prefrontal repetitive transcraneal magnetic stimulation in obssesive-compulsive disorder: a preliminary study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>6</NO>
<PG>867-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sachdev-2001" NAME="Sachdev 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sachdev SP, McBride R, Loo CK, Mitchell PB, Malhi GS, Croker VM</AU>
<TI>Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: A preliminary investigation</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>12</NO>
<PG>981-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-1998" NAME="Greenberg 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg BD, Ziemann U, Harmon A, Murphy DL, Wassermann EM</AU>
<TI>Decreased neuronal inhibition in cerebral cortex in obsessive-compulsive disorder disorder on transcranial magnetic stimulation</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9131</NO>
<PG>881-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-2000" NAME="Greenberg 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg BD, Ziemann U, Cora-Locatelli G, Harmon A, Murphy DL, Keel JC et al</AU>
<TI>Altered cortical excitability in obsessive-compulsive disorder</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>1</NO>
<PG>142-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziemann-1997" NAME="Ziemann 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ziemann U, Paulus W, Rothenberger A</AU>
<TI>Decreased motor inhibition in tourette's disorder: evidence from transcranial magnetic stimulation</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>9</NO>
<PG>1277-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>APA</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barker-1985" NAME="Barker 1985" TYPE="JOURNAL_ARTICLE">
<AU>Barker AT, Jalinous R, Freeston H</AU>
<TI>Non-invasive stimulation of the human motor cortex</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<NO>8437</NO>
<PG>1106-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1992" NAME="Chalmers 1992" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers I, Dickersin K, Chalmers TC</AU>
<TI>Getting to grips with Archie Cochrane's agenda</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>305</VL>
<NO>6857</NO>
<PG>786-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2001" NAME="Clarke 2001" TYPE="BOOK">
<AU>Clarke M, Oxman AD</AU>
<SO>Cochrane reviewers Handbook 4.1.3</SO>
<YR>2001</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grafman-1999" NAME="Grafman 1999" TYPE="JOURNAL_ARTICLE">
<AU>Grafman J, Wassermann E</AU>
<TI>Transcraneal magnetic stimulation can measure and modulate learning and memory</TI>
<SO>Neuropsychologia</SO>
<YR>1999</YR>
<VL>37</VL>
<NO>2</NO>
<PG>159-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ji-1998" NAME="Ji 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ji RR, Schlaepfer TE, Aizenman CD, Epstein CM, Qiu D, Huang JC et al</AU>
<TI>Repetitive transcranial magnetic stimulation activates specific regions in the rat brain</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1998</YR>
<VL>95</VL>
<NO>26</NO>
<PG>15635-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kujirai-1993" NAME="Kujirai 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kujirai T</AU>
<TI>Corticocortical inhibition in human motor cortex</TI>
<SO>Journal of Physiology</SO>
<YR>1993</YR>
<VL>471</VL>
<NO>1</NO>
<PG>501-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1996" NAME="Mulrow 1996" TYPE="BOOK">
<AU>Mulrow CD, Oxman AD</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1996</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Post-1999" NAME="Post 1999" TYPE="JOURNAL_ARTICLE">
<AU>Post RM, Kimbrell TA, McCann UD, Dunn RT, Osuch EA, Speer AM et al</AU>
<TI>Repetitive transcraneal magnetic stimulation as a neuropsychiatric tool: present status and future potential</TI>
<SO>Journal of ECT</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>1</NO>
<PG>39-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wassermann-2001" NAME="Wassermann 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wassermann EM, Greenberg BD, Nguyen MB, Murphy DL</AU>
<TI>Motor cortex excitability correlates with an anxiety-related personality trait</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>5</NO>
<PG>377-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wayne-1999" NAME="Wayne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wayne K, Goodman MD</AU>
<TI>Obsessive-Compulsive Disorder: Diagnosis and treatment</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>suppl 18</NO>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitehead-1991" NAME="Whitehead 1991" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead A, Whitehead J</AU>
<TI>A general parametric approach to the meta-analysis of randomised clinical trials</TI>
<SO>Statistics in Medicine</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>11</NO>
<PG>1665-77</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Alonso-2001">
<CHAR_METHODS>
<P>Parallel randomised control-placebo double-blind<BR/>6 weeks treatment + four weeks follow-up post treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients:<BR/>Randomised: 18<BR/>Mean age: 35.27 (12.18).<BR/>Women: 12<BR/>Men: 6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>rTMS (110% of motor threshold) over right dorsolateral prefrontal cortex and low frequency versus sham TMS at 20% motor threshold.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Yale-Brown Obsessive compulsive Scale.<BR/>Hamilton Depression Rating Scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Greenberg-1997">
<CHAR_METHODS>
<P>Cross-over<BR/>randomised double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients:<BR/>Randomised: 12<BR/>Mean age: 36.9 (10.2).<BR/>Women: 6<BR/>Men: 6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>rTMS (80% motor threshold, 20 Hz/2 seconds per minute for 20 minutes) over right lateral prefrontal, left lateral prefrontal and mioccipital (as control) site.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Yale-Brown Obsessive Compulsive Scale. Hamilton Depression Rating Scale. National Institute of Mental health Self-rating Scale.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sachdev-2001">
<CHAR_METHODS>
<P>Parallel<BR/>randomised<BR/>right vs left<BR/>double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients:<BR/>Randomised: 12<BR/>Mean age: 40.5 (13.4)<BR/>Male: 9<BR/>Female: 3</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>rTMS (10 Hz, 30 trains of 5 seconds each, 25 seconds between trains, and 110% resting motor threshold) over right dorsolateral prefrontal cortex and high frequency vs left dorsolateral prefrontal cortex and high frequency</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Yale-Brown obsessive compulsive scale. Montgomery-Asberg Depression rating scale. Beck depression inventory. Spielberger state-trait anxiety inventory-state.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Greenberg-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>12 patients and 12 healthy volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greenberg-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>16 OCD patients and 11 age-matched healthy volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ziemann-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Tourette's disorder (patients and healthy subjects)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Alonso-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Greenberg-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sachdev-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Remission of obsessions and/or compulsions (rTMS vs placebo)</NAME>
<CONT_OUTCOME CHI2="0.23876910155504186" CI_END="0.9382819116274519" CI_START="-4.742667214754981" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9021926515637644" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.8874664628481318" P_Q="0.8874664628481318" P_Z="0.18933887668042174" Q="0.23876910155504186" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="24" UNITS="" WEIGHT="300.0" Z="1.3125373967556802">
<NAME>Yale-Brown Obsessive Compulsive Scale (6 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6218678788241538" CI_START="-5.821867878824157" DF="0.0" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="0.2687802110020916" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="1.1058760013895106">
<NAME>Obsessions</NAME>
<CONT_DATA CI_END="1.6218678788241538" CI_START="-5.821867878824157" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" MEAN_1="12.2" MEAN_2="14.3" ORDER="1828" SD_1="3.1" SD_2="4.6" SE="1.8989470766717012" STUDY_ID="STD-Alonso-2001" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.470802015024591" CI_START="-6.2708020150245884" DF="0.0" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="0.742581625776012" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="0.3284365316672299">
<NAME>Compulsions</NAME>
<CONT_DATA CI_END="4.470802015024591" CI_START="-6.2708020150245884" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="10.3" MEAN_2="11.2" ORDER="1829" SD_1="5.2" SD_2="6.2" SE="2.740255462543593" STUDY_ID="STD-Alonso-2001" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.550703785641001" CI_START="-10.750703785641004" DF="0.0" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" NO="3" P_CHI2="1.0" P_Z="0.42710188526763015" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="0.7941607102182577">
<NAME>Total</NAME>
<CONT_DATA CI_END="4.550703785641001" CI_START="-10.750703785641004" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" MEAN_1="22.5" MEAN_2="25.6" ORDER="1830" SD_1="7.6" SD_2="8.7" SE="3.903492026378432" STUDY_ID="STD-Alonso-2001" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5359261707650858" CI_END="0.273896600301867" CI_START="-5.636101821720187" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.6811026107091602" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.7649360334782493" P_Q="0.7649360334782493" P_Z="0.07535518192871835" Q="0.5359261707650858" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="24" UNITS="" WEIGHT="300.0" Z="1.7782964327927389">
<NAME>Yale-Brown Obsessive Compulsive Scale (10 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0090726740462346" CI_START="-7.009072674046235" DF="0.0" EFFECT_SIZE="-3.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.14247227425425155" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="1.466646387251885">
<NAME>Obsessions</NAME>
<CONT_DATA CI_END="1.0090726740462346" CI_START="-7.009072674046235" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="14.3" ORDER="1831" SD_1="4.2" SD_2="4.4" SE="2.0454828280872954" STUDY_ID="STD-Alonso-2001" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.9062782713583184" CI_START="-6.506278271358316" DF="0.0" EFFECT_SIZE="-1.299999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.6245584570794234" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="0.48940011407367745">
<NAME>Compulsions</NAME>
<CONT_DATA CI_END="3.9062782713583193" CI_START="-6.506278271358317" EFFECT_SIZE="-1.299999999999999" ESTIMABLE="YES" MEAN_1="9.3" MEAN_2="10.6" ORDER="1832" SD_1="5.6" SD_2="5.6" SE="2.6563132345414386" STUDY_ID="STD-Alonso-2001" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.355487742146366" CI_START="-12.755487742146364" DF="0.0" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="1.0" P_Z="0.2528114744623001" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0" Z="1.143547234159627">
<NAME>Total</NAME>
<CONT_DATA CI_END="3.355487742146366" CI_START="-12.755487742146364" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="20.6" MEAN_2="25.3" ORDER="1833" SD_1="9.1" SD_2="8.3" SE="4.110018248134672" STUDY_ID="STD-Alonso-2001" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Depression (rTMS vs placebo)</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.8302043099578276" CI_START="-5.030204309957827" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5833061341149781" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.5485619100084884">
<NAME>Hamilton Depression Rating Scale (6 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.8302043099578276" CI_START="-5.030204309957827" EFFECT_SIZE="-1.0999999999999996" ESTIMABLE="YES" MEAN_1="10.9" MEAN_2="12.0" ORDER="1834" SD_1="4.9" SD_2="3.6" SE="2.005243127403757" STUDY_ID="STD-Alonso-2001" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.4293749181036897" CI_START="-4.829374918103689" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5169632425808286" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="8" UNITS="" WEIGHT="100.0" Z="0.6480335690083341">
<NAME>Hamilton Depression Rating Scale (10 weeks)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.4293749181036897" CI_START="-4.829374918103689" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="12.0" ORDER="1835" SD_1="4.8" SD_2="3.0" SE="1.8517559234413157" STUDY_ID="STD-Alonso-2001" TOTAL_1="10" TOTAL_2="8" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Right dorsolateral prefrontal cortex vs left dorsolateral prefrontal cortex</NAME>
<CONT_OUTCOME CHI2="0.9078933864265488" CI_END="4.3789131278596845" CI_START="-3.823845476289178" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2775338257852532" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.6351166182720367" P_Q="0.6351166182720367" P_Z="0.8944878632262555" Q="0.9078933864265488" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="300.0" Z="0.13262765108205996">
<NAME>Yale-Brown Obsessive Compulsive Scale (2 weeks)</NAME>
<GROUP_LABEL_1>Right</GROUP_LABEL_1>
<GROUP_LABEL_2>Left</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours right</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours left</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.476338931553412" CI_START="-3.816338931553412" DF="0.0" EFFECT_SIZE="2.33" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" NO="1" P_CHI2="1.0" P_Z="0.4574830399203441" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.7429977641705068">
<NAME>Obsessions</NAME>
<CONT_DATA CI_END="8.476338931553412" CI_START="-3.816338931553412" EFFECT_SIZE="2.33" ESTIMABLE="YES" MEAN_1="10.33" MEAN_2="8.0" ORDER="1836" SD_1="3.93" SD_2="6.6" SE="3.13594483369845" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.446871451796651" CI_START="-8.446871451796651" DF="0.0" EFFECT_SIZE="-2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="1.0" P_Z="0.5431638026601654" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.6080356958238528">
<NAME>Compulsions</NAME>
<CONT_DATA CI_END="4.446871451796651" CI_START="-8.446871451796651" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="6.67" MEAN_2="8.67" ORDER="1837" SD_1="5.01" SD_2="6.31" SE="3.289280569770032" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="10.919723074439151" CI_START="-10.259723074439155" DF="0.0" EFFECT_SIZE="0.3299999999999983" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" NO="3" P_CHI2="1.0" P_Z="0.9512979164673405" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="0.06107696210294616">
<NAME>Total</NAME>
<CONT_DATA CI_END="10.919723074439151" CI_START="-10.259723074439155" EFFECT_SIZE="0.3299999999999983" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="16.67" ORDER="1838" SD_1="4.86" SD_2="12.31" SE="5.403019217684374" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3263354780080664" CI_END="0.1774174820111467" CI_START="-5.251297638580803" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.536940078284828" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.8494487135804758" P_Q="0.8494487135804758" P_Z="0.06697293224285254" Q="0.3263354780080664" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="300.0" Z="1.8318556321048232">
<NAME>Yale-Brown Obsessive Compulsive Scale (1month follow-up)</NAME>
<GROUP_LABEL_1>Right</GROUP_LABEL_1>
<GROUP_LABEL_2>Left</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours right</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours left</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.7543743650426271" CI_START="-5.954374365042627" DF="0.0" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="1.0" P_Z="0.28558460206875247" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="1.0678579654492368">
<NAME>Obsessions</NAME>
<CONT_DATA CI_END="1.7543743650426271" CI_START="-5.954374365042627" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="9.5" ORDER="1839" SD_1="1.82" SD_2="4.46" SE="1.9665536690701664" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.0744522579588" CI_START="-6.874452257958801" DF="0.0" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="1.0" P_Z="0.2931288561627572" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.00000000000001" Z="1.0512825462667934">
<NAME>Compulsions</NAME>
<CONT_DATA CI_END="2.0744522579588" CI_START="-6.874452257958801" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="7.0" ORDER="1840" SD_1="3.36" SD_2="4.47" SE="2.282925754377483" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.8587751994547643" CI_START="-11.858775199454765" DF="0.0" EFFECT_SIZE="-4.5" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.03" NO="3" P_CHI2="1.0" P_Z="0.23070415937556887" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0" Z="1.1985469988380315">
<NAME>Total</NAME>
<CONT_DATA CI_END="2.8587751994547643" CI_START="-11.858775199454765" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="16.5" ORDER="1841" SD_1="3.94" SD_2="8.31" SE="3.754546133245225" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.221622231208276" CI_START="-5.221622231208276" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.3642802657657671" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="99.99999999999999" Z="0.907239318775098">
<NAME>Beck Depression Inventory (2 weeks)</NAME>
<GROUP_LABEL_1>Right</GROUP_LABEL_1>
<GROUP_LABEL_2>Left</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours right</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours left</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.221622231208276" CI_START="-5.221622231208276" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="14.17" MEAN_2="9.67" ORDER="1842" SD_1="8.91" SD_2="8.26" SE="4.960102485500341" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.6906879139217287E-34" CI_END="14.0355926399737" CI_START="-12.495592639973701" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7699999999999997" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.9094233600189674" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="0.1137659137480369">
<NAME>Beck Depression Inventory (1 month follow-up)</NAME>
<GROUP_LABEL_1>Right</GROUP_LABEL_1>
<GROUP_LABEL_2>Left</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours right</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours left</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.0355926399737" CI_START="-12.495592639973701" EFFECT_SIZE="0.7699999999999996" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="10.83" ORDER="1843" SD_1="14.64" SD_2="7.78" SE="6.768283878995227" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="19.56201946630313" CI_START="-0.9020194663031305" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="9.33" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.0739083466331634" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="1.7871803348284363">
<NAME>Montgomery-Asberg Depression Rating Scale (2 weeks)</NAME>
<GROUP_LABEL_1>Right</GROUP_LABEL_1>
<GROUP_LABEL_2>Left</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours right</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours left</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.562019466303134" CI_START="-0.9020194663031322" EFFECT_SIZE="9.33" ESTIMABLE="YES" MEAN_1="15.33" MEAN_2="6.0" ORDER="1844" SD_1="10.35" SD_2="7.51" SE="5.220514023222873" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.770459903170686" CI_START="-3.030459903170687" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.369999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.21023907672593112" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="1.2529083786243074">
<NAME>Montgomery-Asberg Depression Rating Scale (1 month follow-up)</NAME>
<GROUP_LABEL_1>Right</GROUP_LABEL_1>
<GROUP_LABEL_2>Left</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours right</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours left</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.770459903170686" CI_START="-3.030459903170687" EFFECT_SIZE="5.369999999999999" ESTIMABLE="YES" MEAN_1="12.2" MEAN_2="6.83" ORDER="1845" SD_1="8.81" SD_2="5.71" SE="4.286027686953659" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14.793618828289123" CI_START="-13.793618828289123" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.9453392196643303" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="100.00000000000001" Z="0.06856080353356717">
<NAME>Spielberger State-Trait Anxiety Inventory-State (2 weeks)</NAME>
<GROUP_LABEL_1>Right</GROUP_LABEL_1>
<GROUP_LABEL_2>Left</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours right</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours left</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.793618828289123" CI_START="-13.793618828289123" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="45.5" MEAN_2="45.0" ORDER="1846" SD_1="9.67" SD_2="15.02" SE="7.292796674344714" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="17.438714851951293" CI_START="-19.09871485195129" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8299999999999983" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.9290447381403818" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="0.08904677315024628">
<NAME>Spielberger State-Trait Anxiety Inventory-State (1 month follow-up)</NAME>
<GROUP_LABEL_1>Right</GROUP_LABEL_1>
<GROUP_LABEL_2>Left</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours right</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours left</GRAPH_LABEL_2>
<CONT_DATA CI_END="17.438714851951293" CI_START="-19.09871485195129" EFFECT_SIZE="-0.8299999999999983" ESTIMABLE="YES" MEAN_1="44.5" MEAN_2="45.33" ORDER="1847" SD_1="18.96" SD_2="12.72" SE="9.320944158184835" STUDY_ID="STD-Sachdev-2001" TOTAL_1="6" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>